Many are anxiously awaiting results of clinical trials testing NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Anecdotes). During yesterday’s earnings call, Niagen Bioscience CEO Rob Fried provided the following update:

”Last quarter, I discussed 2 studies investigating the effects of NR supplementation on patients experiencing symptoms of long COVID.

One study conducted by Harvard University examined the effect of NR supplementation on fatigue, depressive symptoms, sleep quality and cognition. This study will be published later this month. 

There is also another study conducted in Norway that is undergoing peer review.

We continue to make steady progress toward Parkinson’s disease and ataxia telangiectasia or AT indications.

As mentioned last quarter, the Phase III NOPARK clinical trial was completed in June, and we expect the results of that study to be published in early 2026.

We are incorporating the FDA’s feedback into our strategy for AT and continue to engage with the agency to prepare for an investigational new drug application”

Related:

FOLLOW us on Twitter @RaisingNAD